Retatrutide Side Effects Are Similar to Existing Diabetes and Obesity Injectables The most common side effects for retatrutide were: Nausea (16 to 27 percent of participants, depending on dosage, compared with 3.7 percent of those taking a placebo) Diarrhea (19 to 23 percent, compared with 5 percent taking a placebo) Vomiting (16 to 18 percent, compared with 2 percent taking a placebo) Nerve issues (2 to 4 percent, compared with none taking a placebo) Between 2 and 5 percent of participants on retatrutide stopped taking it before the trial ended, with a greater risk of stopping among those who took the highest dose
Hormonal balance matters
How side effects often change over time For some individuals, side effects may improve over time as the body adjusts to treatment
These medications work like GLP-1 agonists but also target the hormone glucose-dependent insulinotropic polypeptide (GIP)
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial
The Real Cause of "GLP-Shedding" (And Why Everything You've Tried Has Failed) Here's what's actually happening in your body and why it's so much worse than normal hair loss: Step 1: GLP-1 drugs trigger rapid weight loss
